Azitra (NYSEAMERICAN:AZTR) Posts Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Azitra (NYSEAMERICAN:AZTR) issued its quarterly earnings data on Tuesday. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.31, Zacks reports.

Azitra Stock Down 7.9 %

Shares of AZTR stock traded down $0.04 during trading hours on Thursday, hitting $0.45. The company’s stock had a trading volume of 252,599 shares, compared to its average volume of 888,739. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.01. Azitra has a twelve month low of $0.43 and a twelve month high of $68.40.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.